Does the LPL rs328 S447X (G) allele lower triglycerides and cardiovascular risk?

The LPL rs328 polymorphism, specifically the S447X (G) allele, is a well-documented genetic variant that plays a significant role in lipid metabolism and cardiovascular health. For a 64-year-old female, understanding this genotype can provide valuable insights into her inherent metabolic efficiency and long-term cardiovascular risk profile.

Clinical and effectiveness evidence

Extensive clinical data, including meta-analyses involving tens of thousands of subjects, consistently show that carriers of the G allele have a more favorable lipid profile than those with the common CC genotype.

• Triglyceride levels: Research demonstrates that the S447X variant is associated with a 10% to 15% reduction in fasting triglyceride levels. Large-scale studies, such as the ICARIA sub-study (n=1,825), also confirm improved postprandial (after-meal) triglyceride clearance in G allele carriers.
• Cardiovascular risk: The G allele confers significant protection against heart disease. Meta-analyses indicate a 22% to 26% reduction in the risk of coronary artery disease (CAD) for carriers. This protective effect appears to be dose-dependent; individuals with two copies of the G allele (GG genotype) may have up to a 52% lower risk of CAD compared to non-carriers.
• HDL cholesterol: In addition to lowering triglycerides, this variant is frequently associated with higher levels of HDL ("good") cholesterol, further contributing to a healthy lipid profile.

Mechanistic explanations

The "S447X" designation refers to a specific genetic change (C>G) that introduces a premature stop codon, resulting in the removal of the last two amino acids (Serine and Glycine) from the Lipoprotein Lipase (LPL) enzyme.

• Enhanced catalytic activity: This truncation creates a "gain-of-function" version of the enzyme. The shortened LPL protein is more catalytically efficient and shows increased resistance to endogenous inhibitors like Angiopoietin-like protein 4 (ANGPTL4).
• Efficient clearance: LPL is the primary enzyme responsible for breaking down triglycerides in chylomicrons and very-low-density lipoproteins (VLDL). The enhanced activity of the S447X variant leads to more rapid hydrolysis and clearance of these triglyceride-rich particles from the bloodstream.
• Reduced atherogenesis: By accelerating the clearance of triglycerides, the variant reduces the accumulation of atherogenic "remnant" particles that contribute to arterial plaque formation.

Bottom line

The LPL rs328 S447X (G) allele is a beneficial genetic variant strongly associated with lower triglyceride levels and a significantly reduced risk of cardiovascular disease through enhanced enzymatic clearance of fats from the blood.